Pfizer: Activity of neutralizing antibodies after 3rd dose of mRNA vaccines
- Blood drop detection of miRNAs can diagnose early lung cancer
- Will people be arrested if refusing treatment after contracting tuberculosis?
- Vitamin D supplementation may help strengthen Long-COVID recovery
- What bacteria and viruses can cause cancers?
- The world first TIL cell therapy targeting advanced melanoma is coming soon
- The Pros and Cons of Radiotherapy Affecting Antitumor Immunity
Pfizer: Activity of neutralizing antibodies after 3rd dose of mRNA vaccines
Pfizer: Activity of neutralizing antibodies after 3rd dose of mRNA vaccines. Pfizer’s quarterly report shows the activity of neutralizing antibodies after the third dose of mRNA vaccines, and also reveals the great prospects of mRNA vaccines.
On July 28, 2021, Pfizer released its second-quarter financial report, revealing a lot of information.
One of the most striking is the serum neutralization activity data after the third dose of BNT162b2.
The results showed that after the third dose of the 18-55-year-old group, the PRNT50 neutralizing titer rose from 310 to 1,547 for wild-type, and from 241 to 1,321 for Delta. The 65-85-year-old age group rose from 196 to 1,613 for wild-type. , The Delta rose from 124 to 1,479.
Sales of Pfizer vaccines far exceeded expectations.
In the second quarter, Pfizer’s vaccine sales revenue reached $7.8 billion, of which 5.8 billion (74%) were sales outside the United States.
As a result, Pfizer adjusted the annual sales of mRNA COVID-19 vaccine from 26 billion to 33.5 billion US dollars, an increase of 29%.
Pfizer is planning an ambitious mRNA vaccine strategy.
The first breakthrough of mRNA in the prevention of COVID-19, and the advantages of being far ahead of other vaccines, enabled scientists not only to confirm the clinical effects of mRNA vaccines for the first time, but also to expand the application prospects of mRNA vaccines like a sea of stars.
The mRNA vaccine development strategy announced by Pfizer shows its four-step clinical application prospects.
- The first step is a vaccine against COVID-19;
- The second step is a vaccine against influenza and other infectious diseases;
- The third step is a vaccine against some rare diseases and cancer;
- The fourth step is immune tolerance treatment and other medical treatments.
Have to say that this is an ambitious plan. But for mRNA vaccines, these are really worth looking forward to.
Pfizer has made progress in its mRNA vaccine against influenza.
Reading Pfizer’s quarterly report, combined with our understanding, we can see that several trends are predicted:
1. For COVID-19, the third dose of COVID-19 vaccine is necessary;
On July 8th, Pfizer first proposed the need for a third dose of intensive vaccination. Regardless of the US CDC and FDA’s immediate response “no need”; however, it is Pfizer that has the first-hand information, not the bureaucratic CDC and FDA.
Under the American system, companies are where society can truly rely and trust; regardless of their scientific understanding or their sense of social responsibility.
The data of the Israeli Ministry of Health even shows that the protective power of Pfizer vaccine in Israel has dropped from 94%, to 64%, and then to 39%; and only 16% of the vaccine has been vaccinated for more than six months.
Pfizer has implemented vaccine exchange data in Israel, and they have the latest data. Therefore, the results of the third needle replanting shown in the quarterly report are also a rainy day.
Is the protection power 88% or 39%? The truth about Pfizer vaccine preventing the Delta mutant strain is here
2. Pfizer and Moderna’s mRNA vaccines are far ahead of COVID-19 vaccines
In addition to the Novavax protein vaccine, which is still awaiting approval, Pfizer’s mRNA vaccine Moderna’s mRNA vaccine adopts the two core technologies of rationally designed conformational epitope vaccine antigen + liposome nanoparticles to protect stable expressed antigens. It can induce 4 times the neutralizing antibody in the serum of the recovered patient and provide the reason for the ultra-high protection.
The first group’s test results have all been reported. Behind the success and failure of the nCOVID-19 vaccine, it is embarrassing.
Because of the continuous emergence of mutant strains, most other vaccines are difficult to provide effective protection against infection, but they are still sufficient in preventing serious illness and death. In this case, the demand for mRNA vaccines from Pfizer and Moderna has increased significantly.
In Pfizer’s quarterly report, the expected annual sales of mRNA vaccines have been raised by 29%, which shows this very clearly.
3. The long-term clinical application of mRNA vaccines is worth looking forward to
American researchers are using mRNA vaccine technology to fight the COVID-19 coronavirus to develop vaccines against other diseases including influenza and AIDS.
In addition to Pfizer/BioNTech, there are 5 other US companies that are developing new mRNA vaccines and treatments:
1) Moderna Company, located in Cambridge, Massachusetts.
Long before the outbreak of COVID-19, it cooperated with the National Institutes of Health (NIH) to develop a vaccine against HIV, and began clinical trials in 2021.
In fact, the reason why Moderna was the first to initiate a clinical trial of COVID-19 has a lot to do with the research and development of a vaccine against HIV.
2) Gritstone Oncology biotechnology company is working with Gilead Sciences to develop an HIV vaccine.
3) Kernel Biologics is developing an mRNA cancer vaccine.
4) Translate Bio is experimenting with a method for treating cystic fibrosis.
5) Arcturus Therapeutics is developing mRNA vaccines to prevent influenza and COVID-19, as well as treatments for cystic fibrosis and liver disease.
The two mRNA vaccines in Germany try to catch up
1) BioNTech is a partner of Pfizer. All these ambitious plans of Pfizer are based on the cooperation with BioNTech.
2), CureVac company. It is the company that was spotted by former US President Trump and wanted to buy in early 2020, and was later blocked by the European Union. CureVac was favored by Iron Man Elon Musk. It sounds shocking to be able to print clinically needed proteins at will, but when I think about Elon’s project, I believe it.
It should be noted that the development of CureVac’s COVID-19 mRNA vaccine failed miserably. This is in our expectation, because the neutralizing antibodies induced in the phase I clinical trial of CureVac are similar to those of the recovered patients, so it is naturally inadequate for the Delta mutant strain.
We have analyzed the reasons for the failure of the CureVac vaccine. CureVac uses unmodified mRNA vectors, and I often say that Pfizer and Moderna have extended 3’Poly(A) and modified mRNA with m1Ψ; these modifications not only determine the stability of the mRNA vector, And determine its DC tropism and induced signaling pathways. If the mRNA vector itself activates a strong TLR/RIG-I signal, its role is not a vector but an adjuvant, so a large number of vectors may be eliminated by the cell before expression.
But for the development of vaccines for other diseases, all mRNA vaccine companies are almost at the same starting line, and there are almost no conflicts in the research and development projects. COVID-19 has verified that mRNA vaccines are feasible and have few side effects, which means that in a few years, mRNA vaccine companies will be flourishing.
(source:internet, reference only)
Disclaimer of medicaltrend.org